Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Stock Gets Price Target Boost from Morgan Stanley

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT – Get Free Report) had its target price lifted by research analysts at Morgan Stanley from $26.00 to $27.00 in a report issued on Monday, Benzinga reports. The firm currently has an “equal weight” rating on the biotechnology company’s stock. Morgan Stanley‘s price target indicates a potential downside of 22.41% from the stock’s current price.

Several other brokerages have also recently commented on LKFT. Royal Bank Of Canada upgraded shares of Lakefront Biotherapeutics American Depositary Shares from a “sector perform” rating to an “outperform” rating and raised their target price for the stock from $26.00 to $45.00 in a report on Wednesday, September 23rd. TD Cowen began coverage on shares of Lakefront Biotherapeutics American Depositary Shares in a research report on Friday. They issued a “strong-buy” rating on the stock. Weiss Ratings upgraded shares of Lakefront Biotherapeutics American Depositary Shares from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, October 2nd. UBS Group upgraded shares of Lakefront Biotherapeutics American Depositary Shares to a “buy” rating in a research report on Wednesday, September 23rd. Finally, Raymond James Financial reaffirmed a “market perform” rating on shares of Lakefront Biotherapeutics American Depositary Shares in a research note on Thursday. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $36.00.

Read Our Latest Research Report on LKFT

Lakefront Biotherapeutics American Depositary Shares Stock Performance

Shares of NASDAQ:LKFT traded up $0.82 during midday trading on Monday, reaching $34.80. The company had a trading volume of 80,646 shares, compared to its average volume of 199,750. The company has a fifty day simple moving average of $30.36 and a two-hundred day simple moving average of $29.94. The firm has a market cap of $2.29 billion, a price-to-earnings ratio of -24.68 and a beta of 0.22. Lakefront Biotherapeutics American Depositary Shares has a 1-year low of $25.68 and a 1-year high of $36.24.

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT – Get Free Report) last issued its quarterly earnings results on Wednesday, November 11th. The biotechnology company reported ($0.05) earnings per share for the quarter. The company had revenue of $7.87 million during the quarter. Analysts expect that Lakefront Biotherapeutics American Depositary Shares will post -1.46 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Alps Advisors Inc. acquired a new position in Lakefront Biotherapeutics American Depositary Shares during the third quarter valued at $2,617,000. Marshall Wace LLP purchased a new stake in Lakefront Biotherapeutics American Depositary Shares in the 3rd quarter worth about $2,326,000. Entropy Technologies LP acquired a new stake in Lakefront Biotherapeutics American Depositary Shares during the 3rd quarter worth about $887,000. Finally, Commonwealth Equity Services LLC purchased a new stake in shares of Lakefront Biotherapeutics American Depositary Shares in the third quarter worth approximately $279,000. 32.46% of the stock is owned by institutional investors and hedge funds.

About Lakefront Biotherapeutics American Depositary Shares

(Get Free Report)

Galapagos NV, an integrated biopharmaceutical company, engages in the discovery, development, and commercialization of various medicines for high unmet medical need. Its pipeline products include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, psoriatic arthritis, and uveitis. The company’s pipeline products also comprise GLPG1972 that has completed Phase 2b trial for treating osteoarthritis; Toledo molecules, including GLPG3970, GLPG4399, and GLPG4876 for inflammation; and GLPG4716 and Ziritaxestat to treat idiopathic pulmonary fibrosis.

Further Reading

Analyst Recommendations for Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT)

Receive News & Ratings for Lakefront Biotherapeutics American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lakefront Biotherapeutics American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.